The province says it is aiming to provide better care for cancer patients by approving 13 drugs for additional uses and adding two new drugs to the Saskatchewan Cancer Centre’s oncology drug formulary.
According to a news release from the province, the new drugs were recommended by Canada’s Drug Agency Pan-Canadian Oncology Drug Review and then negotiated through the pan-Canadian Pharmaceutical Alliance.
The province says each drug was reviewed for efficacy and determined to be of high quality.
Bringing the drugs into Saskatchewan will benefit more than 450 residents currently undergoing cancer care, the province said.
The drugs will be used to treat conditions like leukemia, lung cancer, breast cancer, prostate cancer and others.
“Adding these new drugs to the formulary ensures we continue to give the best treatment possible to our patients, providing more treatment options for our patients,” Saskatchewan Cancer Agency president and CEO Deb Bulych said in the release.
In the 2025-26 budget the provincial government said it will be providing $279 million to the Saskatchewan Cancer Agency, up $30 million from the previous fiscal year.
